Creative Planning
KRYS icon

Creative Planning’s Krystal Biotech KRYS Stock Holding History

Creative Planning’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.55M Buy
20,318
+4,381
+27% +$1.31M ﹤0.01% 1087
2026
Q1 		$4.12M Buy
15,937
+2,056
+15% +$547K ﹤0.01% 1342
2025
Q4 		$3.42M Buy
13,881
+2,272
+20% +$478K ﹤0.01% 1285
2025
Q3 		$2.05M Buy
11,609
+3,253
+39% +$487K ﹤0.01% 1524
2025
Q2 		$1.15M Sell
8,356
-3,730
-31% -$548K ﹤0.01% 1732
2025
Q1 		$2.18M Buy
12,086
+6,689
+124% +$1.13M ﹤0.01% 1122
2024
Q4 		$845K Sell
5,397
-347
-6% -$61.6K ﹤0.01% 1772
2024
Q3 		$1.05M Buy
5,744
+2,260
+65% +$436K ﹤0.01% 1481
2024
Q2 		$640K Buy
3,484
+618
+22% +$104K ﹤0.01% 1754
2024
Q1 		$510K Buy
+2,866
New +$398K ﹤0.01% 1832

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Creative Planning's KRYS Position: Q2 2026 in Review

Creative Planning increased its Krystal Biotech (KRYS) stake by 27% in Q2 2026, buying an estimated $1.31M and bringing the position to 20,318 shares worth $7.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1087.

Creative Planning first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Creative Planning held 20,318 shares of Krystal Biotech worth $7.55M as of Q2 2026.
  • Creative Planning bought 4,381 Krystal Biotech shares in Q2 2026, an estimated $1.31M.
  • Krystal Biotech made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1087 holding.
  • Creative Planning first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.